FewerJobs.
All jobs

Vice President, Healthcare Law

Revolution Medicines - Redwood City, California, United States

Posted Apr 10, 2026

Benefits

Parental leave
Not verified
Non-birth-parent leave
Not verified
Family-building benefits
  • Fertility benefits: Not verified
  • Adoption assistance: Not verified
  • Surrogacy assistance: Not verified
Mental health support
Not verified
Relocation assistance
Not verified
Childcare support
Not verified
Learning budget
Not verified
Verification
Not verified checked Jun 7, 2026
Salary
$333K-$383K From the posting source checked Jun 20, 2026
401(k) match
Reported from DOL Form 5500 industry filing (not employer-specific)

Was this benefit information wrong? Tell us.

Market context

U.S. role benchmark (BLS OEWS)
$81,444 U.S. median for this role
Projected growth (BLS Employment Projections)
+6.9% - Faster than average

340% above the BLS role benchmark for healthcare aggregate.

Posted salary is far from this role benchmark; treat it as low confidence.

Matched to SOC 29-1141 - Healthcare aggregate by role bucket.

Source: U.S. Bureau of Labor Statistics, OEWS, May 2024 and Employment Projections, 2024-2034.

Role

Role function
Healthcare From the posting source checked Jun 20, 2026
Seniority
Director Plus From the posting source checked Jun 20, 2026

Schedule

Shift type
Not verified
Weekend work
Not verified

Company

Equity
Offered Verified - SEC 10-K source checked Jun 20, 2026

Application

Cover letter
Not verified
Assessment
Not verified
Deadline
Not stated

Where they hire

State eligibility is not yet verified.

About this role

Vice President, Healthcare Law Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a Vice President, Healthcare Law, reporting to the Deputy General Counsel, to join our RevMed team. The Vice President, Healthcare Law will provide strategic legal guidance related to the company's planned commercialization activities, including related to market access, patient access programs, distribution and licensing, and regulatory submissions. A successful candidate will bring proven experience working at a publicly traded life sciences organization, with demonstrated success in driving legal cross-functional strategy. - Serve as a legal advisor to members of the executive team on a wide range of commercialization issues with broad enterprise impact. - Serve as legal representative for Commercialization and Medical-related committees and teams, including promotional review, medical materials, and educational and charitable grants. - Serve as the lead counsel for healthcare regulatory law, including the FDCA and related Regulations, and Guidance Documents, fraud and abuse laws and guidances

Read the full description at www.revmed.com. FewerJobs shows a preview and links to the original posting.

Apply at revmed.com

Apply link not verified; last-live date unavailable.

What verified means

Verified means a displayed claim has field-level provenance to a source FewerJobs pulled: a government or employer source, or the original job posting. Posting-sourced facts are employer-stated and are labeled separately from government records.

Related jobs